[1] Morin D P, Bernard M L, Madias C, et al. The state of the art:atrial fibrillation epidemiology, prevention, and treatment[J]. Mayo Clin Proc,2016,91(12):1778-1810. [2] Odutayo A, Wong C X, Hsiao A J, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death:systematic review and meta-analysis[J]. BMJ,2016,354:i4482. [3] Knecht S, Hocini M, Wright M, et al. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation[J]. Eur Heart J,2008,29(19):2359-2366. [4] Rostock T, Steven D, Hoffmann B, et al. Chronic atrial fibrillation is a biatrial arrhythmia:data from catheter ablation of chronic atrial fibrillation aiming arrhythmia termination using a sequential ablation approach[J]. Circ Arrhythm Electrophysiol,2008,1(5):344-353. [5] Dong J Z, Sang C H, Yu R H, et al. Prospective randomized comparison between a fixed ‘2C3L’ approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation[J]. Europace,2015,17(12):1798-1806. [6] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace,2016,18(11):1609-1678. [7] January C T, Wann L S, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol,2019,74(1):104-132. [8] Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation:results of the ADVANCE study[J]. Eur Heart J,2009,30(9):1128-1135. [9] Soliman E Z, Safford M M, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction[J]. JAMA Intern Med,2014,174(1):107-114. [10] Catapano A L, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias:The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR)[J]. Atherosclerosis,2016,253:281-344. [11] Xia S J, Du X, Li C, et al. Uptake of evidence-based statin therapy among atrial fibrillation patients in China:A report from the CAFR (Chinese Atrial Fibrillation Registry) Study[J]. Int J Cardiol,2016,220:284-289. [12] Jiang C, Lan D H, Du X, et al. Prevalence of modifiable risk factors and relation to stroke and death in patients with atrial fibrillation:A report from the China atrial fibrillation registry study[J]. J Cardiovasc Electrophysiol,2019,30(12):2759-2766. [13] Chen Y W, Bai R, Lin T, et al. Pacing or ablation:which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome?[J]. Pacing Clin Electrophysiol,2014,37(4):403-411. [14] Du X, Patel A, Anderson C S, et al. Epidemiology of Cardiovascular Disease in China and Opportunities for Improvement:JACC International[J]. J Am Coll Cardiol,2019,73(24):3135-3147. [15] Du X, Dong J, Ma C. Is atrial fibrillation a preventable disease?[J]. J Am Coll Cardiol,2017,69(15):1968-1982. |